A method for predicting multi-organ metastatic disease, overall survival, and progression-free survival in subjects with hypertrophic circulating cancer-associated macrophage-like cells (CAML).
CAML size, particularly cells larger than 100 μm, serves as a reliable biomarker for predicting multi-organ metastasis and survival in cancer patients, addressing the inconsistency of CTCs and offering a minimally invasive diagnostic and prognostic tool.
Patent Information
- Application Number
- JP2024500243
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-07-06
- Filing Date
- 2022-07-06
- Publication Date
- 2026-04-07
- Estimated Expiration
- 2042-07-06
AI Technical Summary
Current methods lack consistent biomarkers for predicting multi-organ metastasis and survival in cancer patients, with circulating tumor cells (CTCs) being inconsistent and rare in early stages, and existing research indicates that circulating cancer-associated macrophage-like cells (CAMLs) can provide a universal, minimally invasive prognostic tool.
The use of CAML size as a biomarker, specifically identifying cells larger than 100 μm (heCAML), to diagnose multi-organ metastasis, predict disease progression, and determine overall and progression-free survival in cancer patients.
CAML size accurately predicts multi-organ metastasis and shorter survival times, providing a reliable prognostic tool for cancer patients, with heCAML presence indicating a higher risk of multi-organ metastasis and reduced progression-free and overall survival.